Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition and Method for Reducing Post-Prandial Blood Glucose

a post-prandial blood glucose and composition technology, applied in the direction of biocide, peptide/protein ingredients, plant/algae/fungi/lichens ingredients, etc., can solve the problems of limited usefulness and safety of many anti-obesity products, and achieve the effect of reducing post-prandial glycogen levels, reducing not only the initial rise in blood glucose, and maintaining healthy blood glucose levels

Inactive Publication Date: 2013-05-23
KEMIN FOODS L C
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]The invention consists of a method for reducing post-prandial glycogen levels in the blood of humans by the oral administration of a proteinase inhibitor or a combination of proteinase inhibitors. The proteinase inhibitor or combination is administered prior to the ingestion of a meal and reduces not only the initial rise in blood glucose following a meal (A Glucose or AG) but also the integrated area under the blood glucose curve (AUC) following a meal. The proteinase inhibitor(s) is effective for helping to maintain healthy blood sugar levels and for treating persons, such as those with Type II diabetes, which have adverse health effects due to hyperglycemia. Further, the proteinase inhibitor(s) is expected to reduce the propensity for weight gain by reducing the glycemia experienced by the body.
[0009]In a preferred embodiment, a proteinase inhibitor product isolated from potatoes is administered orally prior to a meal. The potato proteinase inhibitor extract contains between about 15% and about 25% by weight PI2 and also contains other proteins, including Bowman-Birk inhibitor. The potato proteinase inhibitor extract is present in an amount between about 1 mg and about 1000 mg per dose, and preferably between about 5 mg and about 100 mg per dose, and most preferably between about 7.5 mg and about 30 mg per dose. The potato proteinase inhibitor is effective to reduce the blood glucose spike following a meal by between about 5% and about 30% and the AUC glucose by between about 5% and about 40%. Another preferred proteinase inhibitor is Bowman-Birk inhibitor, which is typically isolated from soybeans. The Bowman-Birk inhibitor is present in an amount between about 0.1 mg and about 5.0 mg per dose, and preferably between about 0.5 mg and about 2.0 mg per dose. The Bowman-Birk inhibitor is effective to reduce the blood glucose spike following a meal by between about 10% and about 25% and the AUC glucose by between about 5% and about 30%.
[0010]It is an object of the present invention to reduce post-prandial glycemia in humans by the oral administration of one or more proteinase inhibitors prior to a meal.
[0011]It is a further object of the invention to reduce the initial blood glucose spike following a meal by the oral administration of one or more proteinase inhibitors prior to the meal.
[0012]It is another object of the invention to reduce the total area under the curve blood glucose following a meal by the oral administration of one or more proteinase inhibitors prior to the meal.

Problems solved by technology

Concerns over safety and efficacy of many anti-obesity products have limited their usefulness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition and Method for Reducing Post-Prandial Blood Glucose
  • Composition and Method for Reducing Post-Prandial Blood Glucose
  • Composition and Method for Reducing Post-Prandial Blood Glucose

Examples

Experimental program
Comparison scheme
Effect test

example 1

Methods

Subjects

[0024]Twenty-six men and 13 women, mean age 35 years (range 23-61 years) with a mean body mass index of 27 (range 23-32) participated in the study. Sample size was based on the study by Schwartz et al. who showed significant decreases in mean post-prandial glucose in six type II diabetic subjects following ingestion of a glucose / protein shake in the presence and absence of a high dose of PI2 (1.5 g). All subjects gave informed consent before the study began, and could withdraw at any time.

Study Design

[0025]Subjects were randomly allocated to receive placebo and two of the three following doses: 7.5, 15, or 30 mg PI2 extract. On each study day subjects arrived at 8.00 AM after a 10 hour fast. They were given breakfast and 500 ml of water to drink throughout the morning, but ate nothing further until the test meal. Height and weight of all subjects were recorded during their first visit. Three and a half hours after breakfast the first blood glucose measurement was made...

example 2

[0044]To better understand if the trypsin / chymotrypsin inhibiting activity of the PI2 protein was related to the glucose response to the potato proteinase inhibitor extract, a preparation that purified the PI2 fraction from the potato proteinase inhibitor extract (abbreviated pPI2) was tested along side a preparation of Bowman-Birk inhibitor after meal challenge. The Bowman-Birk inhibitor used was obtained from Sigma-Aldritch and had a stated purity of greater than 80%. Bowman-Birk inhibitor has similar enzyme inhibiting properties as pPI2. The meal challenge was conducted at a breakfast meal instead of a lunch meal, as in the prior study, and consisted of 390 kcal with 100 kcal from fat and 53 g carbohydrate and was provided to individuals who had been fasting for at least 10 hours. Each participant made two visits to the research center and underwent two meal challenges—one for the placebo and one for an active (15 mg pPI2 or 0.8 mg Bowman-Birk inhibitor) and these treatments were...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
time periodaaaaaaaaaa
pore sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

A nutritional intervention composition for reducing post-prandial blood glucose levels in humans, including between about 0.1 mg and about 10 mg of a proteinase inhibitor that is administered prior to the meal. The composition is effective for treating or ameliorating the effects of hyperglycemia and Type II diabetes. The composition also is effective in combating obesity. The proteinase inhibitor is preferably isolated from plant material, such as potatoes, soy, and beans. Potato proteinase inhibitor II and soybean Bowman-Birk inhibitor are included in the group of effective proteinase inhibitors.

Description

[0001]This application is a divisional application of U.S. patent application Ser. No. 10 / 426,678, filed on Apr. 30, 2003, which claims priority to U.S. patent application Ser. No. 09 / 900,555, filed on Jul. 6, 2001, which issued as U.S. Pat. No. 6,767,566 on Jul. 27, 2004.BACKGROUND OF THE INVENTION[0002]The invention relates to compositions for reducing post-prandial blood glucose in humans and, more specifically, to a proteinase inhibitor that delays gastric emptying and reduces post-prandial glycemia which may be beneficial in combating obesity and Type II diabetes.[0003]Regulation of body weight depends on genetic as well as physiologic and lifestyle factors that are known to influence energy balance, such as diet, appetite control, metabolism, and physical activity (Aronne, L. J. (2001) J Clin Psychiatry 62, 13-22; Fernandez-Lopez, J. A., Remesar, X., Foz, M. & Alemany, M. (2002) Drugs 62, 915-44). Despite measures to combat obesity and an increased awareness of the associated ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K36/48A61K36/81A23L1/30A61K38/56
CPCA23L1/3002A23V2002/00A61K36/48A61K36/81A61K38/56A23V2200/328A23V2250/54A23L33/105
Inventor AUSICH, RODSHAO, ANDREWNEWMAN, JERRYDEFREITAS, ZORAIDASHEABAR, FAYAD
Owner KEMIN FOODS L C
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com